Clinical Trials Browser

Phase 3 × OTHER_GOV × Control Groups × Clear all

NCT05063136 2024-11-04

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

Phase 3 Recruiting

Breast Neoplasms